Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Introduction
Shattuck Labs, Inc. is a clinical-stage biotechnology company that is pioneering the development of dual-action fusion proteins, a new class of biologic medicines. Utilizing their proprietary Agonist Redirected Checkpoint (ARC®) platform, the company is dedicated to designing bi-functional fusion proteins capable of simultaneously inhibiting immune checkpoints and activating costimulatory pathways. This approach is instrumental in reactivating anti-tumor immune responses and modulating autoimmune mechanisms, addressing significant unmet needs in oncology and autoimmune disorders.
Innovative Technology and Platform
The core of Shattuck Labs’ innovation lies in its proprietary ARC® platform, which enables the rational design of fusion proteins with a dual mechanism of action. By targeting key immune checkpoints such as CD47 and PD-1 while concurrently stimulating costimulatory receptors like CD40 and OX40, the company is able to enhance the efficacy of immune-mediated treatments without the need for multiple separate therapies. This strategic integration of inhibitory and agonistic functions within a single molecule sets the company apart in the competitive biotechnology landscape.
Product Pipeline and Clinical Programs
Shattuck Labs is actively advancing several clinical programs with its innovative fusion protein candidates:
- SL-172154 (SIRPα-Fc-CD40L): Designed to block inhibitory checkpoints and stimulate immune activation, this candidate is undergoing early-phase clinical evaluation to address advanced cancer indications.
- SL-279252 (PD1-Fc-OX40L): Developed in collaboration with a major pharmaceutical partner, this compound exemplifies the company’s commitment to designing fusion proteins that combine checkpoint inhibition with costimulatory activation.
- Gamma Delta T Cell Engager Platform: Known as gadlen™, this innovative approach aims to bridge gamma delta T cells to tumor antigens, thereby enhancing the immune system’s ability to target and destroy cancer cells.
Throughout these programs, Shattuck Labs maintains a balanced focus on therapeutic innovation, clinical safety, and efficacy, which is thoroughly reflected in their robust preclinical data and ongoing Phase 1 clinical studies.
Market Position and Competitive Landscape
In the dynamic field of biotechnology, Shattuck Labs has carved out a unique niche by leveraging advanced protein engineering and novel therapeutic strategies. The company’s dual-action approach not only positions it as an innovator in the development of biologic medicines but also enables it to address complex diseases with limited treatment options. With clinical programs targeting both hematologic malignancies and autoimmune conditions, Shattuck Labs stands as a significant contributor in the realm of precision immunotherapy and therapeutic innovation.
Expertise, Experience, and Corporate Profile
With offices located in Austin, Texas and Durham, North Carolina, Shattuck Labs benefits from a strong foundation in regional biotech hubs known for their robust research and development ecosystems. The company’s leadership and scientific teams bring extensive expertise in protein engineering, immuno-oncology, and drug development. Their work not only reflects a deep understanding of molecular biology and immune regulation but also underscores a disciplined approach to clinical development that is critical for advancing novel therapeutics safely and effectively.
Understanding the Bi-Functional Fusion Protein Approach
At the heart of Shattuck Labs’ operations is the concept of a bi-functional fusion protein – a therapeutic designed to perform two critical functions within one molecule. This innovative approach allows for:
- Simultaneous inactivation of inhibitory checkpoints that normally prevent an effective immune response.
- Activation of costimulatory pathways that enhance the body's ability to combat cancer cells or manage autoimmune responses.
This dual mechanism is a testament to the company’s expertise in synthesizing complex biological data and leveraging cutting-edge protein design to create more potent therapies with a potentially improved safety profile.
Conclusion
Shattuck Labs, Inc. represents a forward-thinking force in the biotechnology industry. By integrating innovative dual-action fusion proteins with state-of-the-art research and a well-structured clinical development program, the company continues to bolster its position as an informed and experienced player in the field of biologic medicine. Investors and industry stakeholders will find that the company not only addresses pressing medical challenges but also exemplifies a commitment to scientific rigor and therapeutic innovation.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), announced its participation in Citi's 2021 Virtual Immuno-Oncology Day Conference on February 17-18, 2021. CEO Taylor Schreiber and VP of Finance Andrew Neill will present on the company's innovative bi-functional fusion proteins designed to treat cancer and autoimmune diseases. Shattuck's lead program, SL-172154, is currently undergoing a Phase 1 trial targeting the CD47 checkpoint, while a second program, SL-279252, is in collaboration with Takeda Pharmaceuticals.
Shattuck Labs, a clinical-stage biotechnology company listed on NASDAQ under the symbol STTK, announced its participation in the H.C. Wainwright BioConnect 2021 Conference, set for January 11-14, 2021. The presentation will be led by Andrew Neill, Vice President of Finance and Corporate Strategy, on January 11 at 6:00 a.m. EST. Attendees can access the session via a dedicated webcast link. Shattuck specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatments.
Shattuck Labs, a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Taylor Schreiber will speak on January 14 at 5:20 p.m. EST. The presentation can be accessed live via webcast, with a replay available for 30 days. Shattuck's lead program is SL-172154, currently in Phase 1 trials, aiming to block the CD47 immune checkpoint while activating the CD40 pathway.
Shattuck Labs, a clinical-stage biotechnology firm, announced its inclusion in the Russell 2000® and 3000® Indexes effective December 21, 2020. This milestone is seen as a reflection of investor confidence and is expected to enhance the company's visibility in the investment community, expanding its institutional shareholder base. The Russell indexes, managed by FTSE Russell, are pivotal for asset managers, with about $9 trillion in assets benchmarked against them. Shattuck specializes in bi-functional fusion proteins targeting cancer and autoimmune diseases, including ongoing Phase 1 trials for lead programs.
Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.
Shattuck Labs (NASDAQ: STTK) announced the initiation of a Phase 1 clinical trial for its CD47 checkpoint inhibitor, SL-172154, targeting ovarian cancer. The company raised approximately $232.3 million in its October 2020 IPO, extending its cash runway into 2024. Financial results for Q3 2020 show a net loss of $11.8 million, increasing from $7.3 million in Q3 2019. R&D expenses rose to $11.8 million, up from $7.9 million in the same period last year. Shattuck remains focused on advancing its clinical trials and maintaining its pipeline through ongoing funding.
Shattuck Labs, a clinical-stage biotechnology firm (NASDAQ: STTK), announced the presentation of preclinical data from its GADLEN™ platform at the SITC Annual Meeting on November 11, 2020. The research showcases the potential of a butyrophilin heterodimer to activate gamma delta T cells, targeting lymphoma cells with the CD19 antigen. CEO Taylor Schreiber emphasized the promise of enhancing gamma delta T cell effectiveness for treating resistant cancers. This milestone represents significant progress in developing GADLEN compounds for various tumor targets.
Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its upcoming presentation at the virtual CD47|SIRPα Summit 2020 on November 5, 2020. The presentation, titled "CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity," will be delivered by CEO Taylor Schreiber at 10:45 a.m. EST. Shattuck is developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program SL-172154 currently in a Phase 1 trial.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is the core focus of Shattuck Labs, Inc.?
How does the ARC® platform work?
Which therapeutic areas does Shattuck Labs target?
What distinguishes Shattuck Labs from other biotech companies?
Can you elaborate on the company’s product pipeline?
Does Shattuck Labs collaborate with other companies?
